Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey

Serarslan, Alparslan; Gursel, Bilge; Okumus, Nilgun Ozbek; Meydan, Deniz; Süllü, Yüksel; Gönüllü, Güzin

doi:10.7314/apjcp.2015.16.15.6673

Cited by 8 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, over 10% MBC patients declined surgical treatment in our study. In man, there is no enough gland tissue to delay the infiltration of the tumor to the surrounding area, leading to invasion of the pectoralis major muscle and skin ( 40 ). In addition, MBC is often located in the areola area, making it inappropriate to treat using conserving surgery.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors of male breast cancer vs. female breast cancer

Sang¹,

Pan²,

Chen³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: To investigate the clinicopathological features and prognostic factors of male breast cancer (MBC) and female breast cancer (FBC) patients.Methods: A total of 90 MBC and 180 FBC patients were included in this retrospective study. The clinicopathological features, disease-free survival rate (DFSR), and overall survival rate (OSR) were compared between the two groups. Cox proportional hazard model was used to analyze the factors affecting the survival rates.Results: Most MBC were invasive ductal carcinoma (70/90, 77.8%) and luminal type (83/90, 92.2%), and were treated with modified radical mastectomy (78/90, 86.7%). Compared with women, there were more patients with one-set age of ≥70 years old, having family history of cancer, comorbid with underlying diseases in the male patients. They also had higher portion of patients at T3 and T4 stages. The rates of male patients receiving adjuvant radiotherapy, chemotherapy and endocrine therapy were lower (P<0.05) than female patients. OSR and DFSR were lower in the male patients than in the female patients (P<0.05). T stage, TNM stage, the status of progesterone receptor and endocrine therapy were independent prognostic factors for survival of MBC (P<0.05); TNM stage, chemotherapy or endocrine therapy were independent factors for survival of FBC (P<0.05).Conclusions: Compared with FBC, MBC occurs later with more underlying diseases and lower survival rates. MBC is less active in adjuvant therapy and endocrine therapy. Since MBC has more luminal type, increased endocrine therapy may improve the survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors of male breast cancer vs. female breast cancer

Sang¹,

Pan²,

Chen³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…In another study, Serarslan and colleagues compared the dosimetric differences using physical WB-CRT, field-in-field IMRT and IMRT. 15 Techniques were evaluated with respect to expected target volume coverage and the dose to OAR. They suggested that IMRT was superior to WB-CRT (p = 0•005 for the V 20 for the right kidney; p = 0•001 for the D-mean in the left kidney; p = 0•023 for the V 20 for the left kidney).…”

Section: Discussionmentioning

confidence: 99%

“…CI is defined by a ratio of reference isodose volume to target volume of PTV. 15 The value of CI varies between 0 and 1, and a value closer to one indicates better conformity of dose to the PTV. The 95% isodose volume was taken as the reference volume of the PTV.…”

Section: Himentioning

confidence: 99%

Comparing treatment plans for stomach cancer: three-dimensional conformal radiotherapy (3D-CRT), physical wedge-based conformal RT (WB-CRT) and intensity-modulated radiotherapy (IMRT)

Inan

Gül

2021

J Radiother Pract

View full text Add to dashboard Cite

Objective: The aim of this study was to find the optimal radiotherapy (RT) method using three-dimensional (3D) conformal RT (CRT), physical wedge-based CRT (WB-CRT) and dynamic intensity-modulated RT (D-IMRT) techniques for stomach cancer. Methods: Ten patients with gastric cancer were selected for this study. For each patient, three different treatment plans were generated. 3D-CRT, WB-CRT and IMRT plans were evaluated in terms of dosimetry. Treatment plans were compared with respect to the planning target volume and organs at risk (OARs) volumes including right and left kidney doses (V13, V20 and V28), heart mean and maximum doses, spinal cord maximum doses, dose homogeneity index, conformity index (CI), delivery time and the monitor unit counts for the treatment. Statistical analysis was performed using the SPSS (Statistical Package for the Social Sciences) v25.1 software (IBM Inc., Chicago, IL, USA). Results: In stomach plans, IMRT showed a significantly lower dose for the left and right kidneys than that of WB-CRT or 3D-CRT (p < 0·05). Compared with WB-CRT or 3D-CRT, IMRT reduced the V28, V20, V13 and mean dose to bilateral kidneys (p < 0·05). IMRT plans indicated better dosimetry for at the Dmean of the liver and heart. Concerning the calculated CI, values for IMRT plans gave significant results than other plans (p < 0·05). Conclusions: IMRT plans provided better protection for the kidneys, liver, heart and spinal cord. For the treatment of stomach cancer, considering the dose to the OARs, IMRT appears to be the most superior technique.

show abstract

“…7 Studies have revealed relation of male breast carcinoma with Klinefelter's syndrome, gynecomastia, first-degree relatives with male breast carcinoma, hyperestrogenism, diabetes, alcohol intake, physical inactivity, increased BMI, orchitis/epididymitis, Lynch Syndrome, and Li-Fraumeni Syndrome. 2,7,8 Several other risk associations are to be unfolded as in female breast carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…However, special types of breast carcinomas can occur in male breast carcinoma as in female breast carcinoma. [8][9][10] Lymph node metastasis was seen in two out of three (66%) of our cases. In a case series of 229 patients, lymph node metastasis was seen in 57% of the patients with male breast carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Male Breast Cancer: A Rare Entity

et al. 2018

View full text Add to dashboard Cite

Male breast carcinoma is a rare malignancy (<1% of all breast carcinomas, 0.2% of all male malignancies). Its common histopathological type is infiltrating carcinoma, not otherwise specified. Three male patients aged 56 (stage –IIIB), 64 (T4bN0M0) and 78 (T2N0MO) years presented with a breast lump within a year. Their hematological and biochemical parameters were within normal limits. Two of them had palpable regional lymph nodes. Male breast carcinoma occurs in older males as in our cases. Two cases showed infiltrating ductal carcinoma, not otherwise specified on histopathological evaluation, and one showed special type with apocrine differentiation. Their two-year follow-up was uneventful after modified radical mastectomy and chemotherapy. Male breast carcinoma is associated with risk factors different from and overlapping with female breast carcinoma. Male breast carcinoma differs from female breast carcinoma on clinical presentation, biological behaviour and prognosis.

show abstract

Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey

Cited by 8 publications

References 31 publications

Clinical features and prognostic factors of male breast cancer vs. female breast cancer

Clinical features and prognostic factors of male breast cancer vs. female breast cancer

Comparing treatment plans for stomach cancer: three-dimensional conformal radiotherapy (3D-CRT), physical wedge-based conformal RT (WB-CRT) and intensity-modulated radiotherapy (IMRT)

Male Breast Cancer: A Rare Entity

Contact Info

Product

Resources

About